The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Recent advances and new strategies on leishmaniasis treatment
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Bilia, A. R., Guccione, C., Isacchi, B., Righeschi, C., Firenzuoli, F., & Bergonzi, M. C. (2014) · Evidence-Based Complementary and Alternative Medicine · doi:10.1155/2014/651593 · Cited by 514
RetractedDrug repurposing: progress, challenges and recommendations
Pushpakom, S., Iorio, F., Eyers, P. A., Escott, K. J., Hopper, S., Wells, A., Doig, A., Guilliams, T., Latimer, J., McNamee, C., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.168 · Cited by 4,718
Drug repositioning: identifying and developing new uses for existing drugs
Ashburn, T. T., & Thor, K. B. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1468 · Cited by 3,237
Burza, S., Croft, S. L., & Boelaert, M. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31204-2 · Cited by 1,913
Predicting new molecular targets for known drugs
Keiser, M. J., Setola, V., Irwin, J. J., Laggner, C., Abbas, A. I., Hufeisen, S. J., Jensen, N. H., Kuijer, M. B., Matos, R. C., Tran, T. B., et al. (2009) · Nature · doi:10.1038/nature08506 · Cited by 1,667 · cited 1×
“Another important tool is called signature matching that is based on the comparison between the characteristic (signature) of a drug or molecule compared with that of another drug or molecule (Keiser et al. 2009).”
BackgroundReithinger, R., Dujardin, J.-C., Louzir, H., Pirmez, C., Alexander, B., & Brooker, S. (2007) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(07)70209-8 · Cited by 1,334
The Relationship between Leishmaniasis and AIDS: the Second 10 Years
Alvar, J., Aparicio, P., Aseffa, A., Den Boer, M., Cañavate, C., Dedet, J.-P., Gradoni, L., Ter Horst, R., López-Vélez, R., & Moreno, J. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00061-07 · Cited by 937
Alvar, J., Yactayo, S., & Bern, C. (2006) · Trends in Parasitology · doi:10.1016/j.pt.2006.09.004 · Cited by 812
Oral Miltefosine for Indian Visceral Leishmaniasis
Sundar, S., Jha, T. K., Thakur, C. P., Engel, J., Sindermann, H., Fischer, C., Junge, K., Bryceson, A., & Berman, J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021556 · Cited by 779
Amphotericin primarily kills yeast by simply binding ergosterol
Gray, K. C., Palacios, D. S., Dailey, I., Endo, M. M., Uno, B. E., Wilcock, B. C., & Burke, M. D. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1117280109 · Cited by 608 · cited 1×
“This drug binds to membrane sterols with particular affinity towards ergosterol, forming complexes that arrange into ion channels and increase membrane permeability (Gray et al. 2012).”
BackgroundDrug resistance in Indian visceral leishmaniasis
Sundar, S. (2001) · Tropical Medicine & International Health · doi:10.1046/j.1365-3156.2001.00778.x · Cited by 585
Pentavalent Antimonials: New Perspectives for Old Drugs
Frézard, F., Demicheli, C., & Ribeiro, R. R. (2009) · Molecules · doi:10.3390/molecules14072317 · Cited by 496
Injectable Paromomycin for Visceral Leishmaniasis in India
Sundar, S., Jha, T. K., Thakur, C. P., Sinha, P. K., & Bhattacharya, S. K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066536 · Cited by 471
Miltefosine for New World Cutaneous Leishmaniasis
Soto, J., Arana, B. A., Toledo, J., Rizzo, N., Vega, J. C., Diaz, A., Luz, M., Gutierrez, P., Arboleda, M., Berman, J. D., et al. (2004) · Clinical Infectious Diseases · doi:10.1086/383321 · Cited by 385
Fluconazole for the Treatment of Cutaneous Leishmaniasis Caused by Leishmania major
Alrajhi, A. A., Ibrahim, E. A., De Vol, E. B., Khairat, M., Faris, R. M., & Maguire, J. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011882 · Cited by 328
An update on pharmacotherapy for leishmaniasis
Sundar, S., & Chakravarty, J. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.973850 · Cited by 320
Treatment of Visceral Leishmaniasis with Pentavalent Antimony and Interferon Gamma
Badaro, R., Falcoff, E., Badaro, F. S., Carvalho, E. M., Pedral-Sampaio, D., Barral, A., Carvalho, J. S., Barral-Netto, M., Brandely, M., Silva, L., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199001043220104 · Cited by 310
Leishmaniasis: an update of current pharmacotherapy
Sundar, S., & Chakravarty, J. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.755515 · Cited by 261
Sundar, S., Rai, M., Chakravarty, J., Agarwal, D., Agrawal, N., Vaillant, M., Olliaro, P., & Murray, H. W. (2008) · Clinical Infectious Diseases · doi:10.1086/591972 · Cited by 209
Cota, G. F., de Sousa, M. R., Fereguetti, T. O., & Rabello, A. (2013) · PLoS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0002195 · Cited by 189
Current and emerging medications for the treatment of leishmaniasis
Chakravarty, J., & Sundar, S. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1609940 · Cited by 182
Bailey, F., Mondragon-Shem, K., Hotez, P., Ruiz-Postigo, J. A., Al-Salem, W., Acosta-Serrano, Á., & Molyneux, D. H. (2017) · PLOS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0005739 · Cited by 175
Accelerated Healing of Skin Ulcers by Electrotherapy: Preliminary Clinical Results
WOLCOTT, L. E., WHEELER, P. C., HARDWICKE, H. M., & ROWLEY, B. A. (1969) · Southern Medical Journal · doi:10.1097/00007611-196907000-00008 · Cited by 169
Nanoparticle Therapeutics: FDA Approval, Clinical Trials, Regulatory Pathways, and Case Study
Eifler, A. C., & Thaxton, C. S. (2011) · Methods in Molecular Biology · doi:10.1007/978-1-61779-052-2_21 · Cited by 168
Laboratory confirmed miltefosine resistant cases of visceral leishmaniasis from India
Srivastava, S., Mishra, J., Gupta, A. K., Singh, A., Shankar, P., & Singh, S. (2017) · Parasites & Vectors · doi:10.1186/s13071-017-1969-z · Cited by 167
Liposomal amphotericin B as a treatment for human leishmaniasis
Balasegaram, M., Ritmeijer, K., Lima, M. A., Burza, S., Ortiz Genovese, G., Milani, B., Gaspani, S., Potet, J., & Chappuis, F. (2012) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2012.748036 · Cited by 160
Jebali, A., & Kazemi, B. (2013) · Toxicology in Vitro · doi:10.1016/j.tiv.2013.06.002 · Cited by 126
Applications of Nanomaterials in Leishmaniasis: A Focus on Recent Advances and Challenges
Saleem, K., Khursheed, Z., Hano, C., Anjum, I., & Anjum, S. (2019) · Nanomaterials · doi:10.3390/nano9121749 · Cited by 125
Roatt, B. M., Aguiar‐Soares, R. D. D. O., Coura‐Vital, W., Ker, H. G., Moreira, N. D. D., Vitoriano-Souza, J., Giunchetti, R. C., Carneiro, C. M., & Reis, A. B. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00272 · Cited by 115
Self-citationWasunna, M. K., Njenga, S., Balasegaram, M., Alexander, N. D. E., Omollo, R., Edwards, T., Dorlo, T. P. C., Younis, B. M., Ali, M. H. S., Elamin, M. Y., et al. (2016) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0004880 · Cited by 106
Kim, D. H., Chung, H. J., Bleys, J., & Ghohestani, R. F. (2009) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0000381 · Cited by 100
Therapeutic Options for Visceral Leishmaniasis
Monge‐Maíllo, B., & López‐Vélez, R. (2013) · Drugs · doi:10.1007/s40265-013-0133-0 · Cited by 92
Uzun, S., Durdu, M., Çulha, G., et al. (2004) · Journal of Parasitology · doi:10.1645/ge-185r · Cited by 85
Changing response to diamidine compounds in cases of kala-azar unresponsive to antimonial.
Sn, J., Singh, N. K., & Tk, J. (1991) · PubMed · Cited by 85
Multi-target drugs active against leishmaniasis: A paradigm of drug repurposing
Braga, S. S. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111660 · Cited by 85
Kimutai, R., Musa, A. M., Njoroge, S., Omollo, R., Alves, F. P., Hailu, A., Khalil, E. A. G., Diro, E., Soipei, P., Younis, B. M., et al. (2017) · Clinical Drug Investigation · doi:10.1007/s40261-016-0481-0 · Cited by 78
Treatment of cutaneous leishmaniasis with nitric-oxide donor
López-Jaramillo, P. A., Ruano, C., Rivera, J., Terán, E., Salazar-Irigoyen, R., Esplugues, J. V., & Moncada, S. (1998) · The Lancet · doi:10.1016/s0140-6736(05)79119-4 · Cited by 74
Koester, L., Mattos, C., Argenta, D. F., Melchiades, G. D. L., Cordeiro, M. N. S., Tonini, M. L., de Moraes, M. H., Weber, T., Roman, S. S., Nunes, R. D. C., et al. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s83929 · Cited by 72
Efficacy of azole therapy for tegumentary leishmaniasis: A systematic review and meta-analysis
Galvão, E. L., Rabello, A., & Cota, G. (2017) · PLoS ONE · doi:10.1371/journal.pone.0186117 · Cited by 72
Kumar, P., Shivam, P., Mandal, S., Prasanna, P., Kumar, S., Prasad, S. R., Kumar, A., Das, P., Ali, V., Singh, S. K., et al. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s196421 · Cited by 68
Mahajan, R., Das, P. K., Isaakidis, P., Sunyoto, T., Sagili, K. D., Lima, M. A., Mitra, G., Kumar, D., Pandey, K., Geertruyden, J. V., et al. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ530 · Cited by 65
López-Jaramillo, P. A., Rincón, M. Y., Garcia, R. G., Silva, S. Y., Smith, E., Kampeerapappun, P., García, C., Smith, D. J. B., López, M., & Vélez, I. D. (2010) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.2010.09-0287 · Cited by 56
Giladi, M., Porat, Y., Blatt, A., Shmueli, E., Wasserman, Y., Kirson, E. D., & Palti, Y. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01841-09 · Cited by 42
Dar, M. J., Khalid, S., McElroy, C. A., Satoskar, A. R., & Khan, G. M. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.118900 · Cited by 42
Bustamante, C., Ochoa, R., Asela, C., & Muskus, C. (2019) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-019-00230-y · Cited by 31
Innovative Solutions for the Control of Leishmaniases: Nanoscale Drug Delivery Systems
Wagner, V., Minguez-Menendez, A., Pena, J., & Fernandez‐Prada, C. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190621154552 · Cited by 13
Metadata
- Authors
- Roatt, B. M., de Oliveira Cardoso, J. M., De Brito, R. C. F., Coura-Vital, W., de Oliveira Aguiar-Soares, R. D., & Reis, A. B.
- Venue
- Applied Microbiology and Biotechnology
- Published
- 2020-09-02
- Volume
- 104
- Issue
- 21
- Pages
- 8965-8977
- ISSN
- 0175-7598 (ISSN-L)
- 1432-0614
- OpenAlex
- W3082435589
- Cited by
- 253
- References
- 46
- FWCI
- 20.65
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.